The Company offers research, discovery, and development of novel compounds that target cancer stem cells. Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the. This has resulted in an Earnings ESP of -1.70%. Andrew Cole / Gloria Labbad (U.S.) The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. About CD123 Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The firm owned 16,297 shares of the biopharmaceutical company’s stock after selling 40,437 shares during the period. ELZONRIS® (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN. development and commercialization of novel oncology therapeutics. In terms of biotechnology stocks, there are a number of aspects that have the ability to lead to price movement in the market. Sard Verbinnen & Co Menarini is also committed to oncology, with several new investigational drugs in development for the treatment of a variety of tumors. * Required fields About Stemline. Questions for the Investor Relations Department can be submitted through the form below. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. FLORENCE – June 10, 2020 – Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash consideration up to $677 million on a fully diluted basis. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. Stemline Therapeutics, Inc. (STML) is working its way for to the bottom in the market in today’s trading session. FLORENCE, Italy-- (BUSINESS WIRE)--Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has … Media Andy Brimmer / … NEW YORK , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that management will present at the 38 th Annual J.P. Under the terms of the agreement, Stemline shareholders will have the right to receive (i) $11.50 in cash plus (ii) one contingent value right for each share of Stemline common stock owned. Elcin Barker Ergun, CEO of Menarini Group, commented, “We are very excited to complete the acquisition of Stemline and to welcome their accomplished team to Menarini. On May 3, 2020, Stemline Therapeutics, Inc., a Delaware corporation (“Stemline”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Berlin-Chemie AG, a company formed under the laws of Germany (“Berlin-Chemie”), and Mercury Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Berlin-Chemie (“Purchaser”). FLORENCE, Italy and NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreement under which … For full prescribing information in the U.S., visit www.ELZONRIS.com. Stemline’s additional pipeline candidates include felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing) and SL-1001 (RET kinase inhibitor, IND-enabling studies ongoing). A worker with the title physician salary at Stemline Therapeutics can earn an average yearly salary of $246,393. Stemline is a commercial-stage biopharmaceutical company committed to applying our scientific leadership and commercial expertise to transform the lives of patients with cancer. BERLIN-CHEMIE AG - Glienicker Weg 125 - 12489 Berlin - Deutschland Deutsche Bank AG’s holdings […] The addition of ELZONRIS, which has potential to treat many other malignancies, as well as the other attractive pipeline assets augments our research and development capabilities and will accelerate our efforts to deliver novel oncology therapeutics to patients in need.”. File No.) … Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. ELZONRIS is also being evaluated in additional clinical trials in other CD123+ indications, including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), acute myeloid leukemia (AML), and others are planned including a CD123+ all-comers trial. STEMLINE THERAPEUTICS, INC. : Financial news and information Stock STEMLINE THERAPEUTICS, INC. | Nasdaq: | Nasdaq The company, one that is focused in the biotechnology space, is currently priced at $13.70 after a move down of -5.12% so far in today’s session. Stemline Therapeutics, Inc. (STML) is working its way for to the top in the market today. Search for: Filter Results. Eleventh Floor. Shares of Stemline Therapeutics (NASDAQ:STML) are up 153% to $12.02 at 1:11 p.m. EDT after the company announced it is being acquired by a … © 2021 – Stemline Therapeutics, Inc. All rights reserved | Privacy & Terms of Use. In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). Email: menarini-svc@sardverb.com, KONTAKT About Stemline Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. In addition, CD123+ cells have been detected in the tumor microenvironment of several solid tumors as well as in certain autoimmune disorders including cutaneous lupus and scleroderma. Its global platform extends throughout Europe, Central America, Africa, the Middle East and Asia and generates over $4.2 billion in annual sales. Employer. Stemline Contacts. The higher paying positions at Stemline Therapeutics include physician, hospitalist, staff pharmacist, and respiratory therapist. Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. Additional pipeline candidates include: felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing), SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing), SL-701 (immunotherapeutic; Phase 2 in glioblastoma patients completed), and SL-901 (novel kinase inhibitor; prior abbreviated European Phase 1, IND-enabling studies ongoing). The Menarini Group is a leading international pharmaceutical company with a presence in over 100 countries, including a direct presence in over 70 countries. CD123 is a cell surface target expressed on a wide range of malignancies including blastic plasmacytoid dendritic cell neoplasm (BPDCN), certain myeloproliferative neoplasms (MPNs) including chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF), acute myeloid leukemia (AML) (and potentially enriched in certain AML subsets), myelodysplastic syndrome (MDS), and chronic myeloid leukemia (CML). Tel. About BPDCN Stemline is developing three clinical stage product candidates, SL-401, SL-701, and SL-801. 750 Lexington Avenue. ELZONRIS (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The World Health Organization (WHO) termed this disease “BPDCN” in 2008; previous names included blastic NK cell lymphoma and agranular CD4+/CD56+ hematodermic neoplasm. For investor and media inquiries, please contact: (I.R.S. FLORENCE – June 10, 2020 – Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash … development and commercialization of novel oncology therapeutics. Stemline launched ELZONRIS for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients, two years or older, following the approval by the United States Food and Drug Administration in December 2018. FLORENCE – June 10, 2020 – Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash … BPDCN typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera. Stemline Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: Pursuant to Sections 141(f) and 242 of the DGCL, the Board of Directors of the Corporation (the “Board” Agreements and Contracts. The transaction, which was announced on 4 May 2020, strengthens Menarini’s oncology portfolio with the addition of both commercial and clinical-stage assets. SECTOR. CD123 has also been reported on multiple myeloma (MM), acute lymphoid leukemia (ALL), hairy cell leukemia (HCL), Hodgkin’s lymphoma (HL), and certain Non-Hodgkin’s lymphomas (NHL). Stemline Therapeutics (STML) was incorporated under the laws of the State of Delaware in August 2003. About ELZONRIS® : +49 30 6707-0 It is the only FDA-approved … ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the. Menarini acquired Stemline for an upfront payment of $11.50 per share in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 per share in cash upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval. Stemline Therapeutics, Inc. related to its sale to Berlin-Chemie AG. treatment of adult and pediatric patients, two years and older, with BPDCN. The stock, one that is focused in the biotech space, is presently trading at $14.55 after climbing 11.67% so far today. treatment of adult and pediatric patients, two years and older, with BPDCN. FDA Approved Biologics and Pending Applications. The Company's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. ELZONRIS® (tagraxofusp), a. targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the. The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers. Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. We are investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Stemline Therapeutics, Inc. (“STML” or the “Company”) (NASDAQ: STML) in connection with the proposed acquisition of the Company by Menarini Group (“Menarini”), a privately-held pharmaceutical company based in Italy. For Stemline Therapeutics, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. Stemline Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware: 001-35619: 45-0522567 (State or other Jurisdiction. On the other hand, the stock currently carries a Zacks Rank of #3. In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA).
Flaconi Guerlain L'instant Magic, Xylocain Gel 2 Erfahrungen, Lidocain Spray Vorzeitiger Samenerguss, Spielplan Dynamo Dresden 2020/21, Orthopäde Altötting öffnungszeiten, Kerncurriculum Niedersachsen Religion Grundschule 2017, Isna High School Timings, Zwei Weihnachtshunde Drehort,
Schreibe einen Kommentar